Patterns of Treatment and Recurrence in Women Diagnosed with ductal carcinoma in situ at Poole Hospital NHS Foundation Trust
Association of Breast Surgery ePoster Library. Fields J. 05/15/17; 166354; P180
Mrs. Jo Fields
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: Knowledge of patterns of treatment and recurrence for women diagnosed with ductal carcinoma in situ (DCIS) is important to inform the development of best practice.
Methods: A retrospective data analysis was undertaken of all women diagnosed with DCIS at Poole Hospital NHS Foundation Trust (PHFT) between January 2010 and December 2014, with median follow up of 48 months (range 24-72). Data was collected on demographics, treatment, histology, time to recurrence, and site/type of recurrence.
Results: 175 women were treated for DCIS from 2010-2014, mean age 62 years (range 36-91). The majority were detected via screening (67%) or surveillance (6%) mammography, however a quarter (26%) presented symptomatically. 66% (n=116) underwent wide local excision (WLE), 30% (n=53) mastectomy, 3% (n=5) primary hormone therapy, and 1% (n=2) no treatment. Of those undergoing WLE, 84% (n=97) received adjuvant radiotherapy, and 44% (n=54) with hormone receptor positive (ER+ve) disease received tamoxifen. After 48 months median follow up, following WLE 4.3% (n=5) developed local recurrence, 2.6% (n=3) ipsilateral recurrence, and 1.7% (3/175) in total contralateral disease. All local recurrences occurred at two years (3 invasive, 2 DCIS). Of those undergoing WLE who received radiotherapy, 3% (n=3/97) developed local/ipsilateral disease compared to 26% (n=5/19) who did not. Of those ER+ve receiving hormone therapy, none (n=70) developed recurrence, compared to 10% (n=7) who did not.
Conclusions. Early findings suggest local recurrence rates are low at PHFT. All occurred early (at 2 years). Adjuvant radiotherapy and hormone therapy (if ER+ve) appeared to reduce risk. Further data collection and a subsequent audit is planned to determine the local recurrence rate and compare this to the BASO standard of <10% at 5 years.
Methods: A retrospective data analysis was undertaken of all women diagnosed with DCIS at Poole Hospital NHS Foundation Trust (PHFT) between January 2010 and December 2014, with median follow up of 48 months (range 24-72). Data was collected on demographics, treatment, histology, time to recurrence, and site/type of recurrence.
Results: 175 women were treated for DCIS from 2010-2014, mean age 62 years (range 36-91). The majority were detected via screening (67%) or surveillance (6%) mammography, however a quarter (26%) presented symptomatically. 66% (n=116) underwent wide local excision (WLE), 30% (n=53) mastectomy, 3% (n=5) primary hormone therapy, and 1% (n=2) no treatment. Of those undergoing WLE, 84% (n=97) received adjuvant radiotherapy, and 44% (n=54) with hormone receptor positive (ER+ve) disease received tamoxifen. After 48 months median follow up, following WLE 4.3% (n=5) developed local recurrence, 2.6% (n=3) ipsilateral recurrence, and 1.7% (3/175) in total contralateral disease. All local recurrences occurred at two years (3 invasive, 2 DCIS). Of those undergoing WLE who received radiotherapy, 3% (n=3/97) developed local/ipsilateral disease compared to 26% (n=5/19) who did not. Of those ER+ve receiving hormone therapy, none (n=70) developed recurrence, compared to 10% (n=7) who did not.
Conclusions. Early findings suggest local recurrence rates are low at PHFT. All occurred early (at 2 years). Adjuvant radiotherapy and hormone therapy (if ER+ve) appeared to reduce risk. Further data collection and a subsequent audit is planned to determine the local recurrence rate and compare this to the BASO standard of <10% at 5 years.
Introduction: Knowledge of patterns of treatment and recurrence for women diagnosed with ductal carcinoma in situ (DCIS) is important to inform the development of best practice.
Methods: A retrospective data analysis was undertaken of all women diagnosed with DCIS at Poole Hospital NHS Foundation Trust (PHFT) between January 2010 and December 2014, with median follow up of 48 months (range 24-72). Data was collected on demographics, treatment, histology, time to recurrence, and site/type of recurrence.
Results: 175 women were treated for DCIS from 2010-2014, mean age 62 years (range 36-91). The majority were detected via screening (67%) or surveillance (6%) mammography, however a quarter (26%) presented symptomatically. 66% (n=116) underwent wide local excision (WLE), 30% (n=53) mastectomy, 3% (n=5) primary hormone therapy, and 1% (n=2) no treatment. Of those undergoing WLE, 84% (n=97) received adjuvant radiotherapy, and 44% (n=54) with hormone receptor positive (ER+ve) disease received tamoxifen. After 48 months median follow up, following WLE 4.3% (n=5) developed local recurrence, 2.6% (n=3) ipsilateral recurrence, and 1.7% (3/175) in total contralateral disease. All local recurrences occurred at two years (3 invasive, 2 DCIS). Of those undergoing WLE who received radiotherapy, 3% (n=3/97) developed local/ipsilateral disease compared to 26% (n=5/19) who did not. Of those ER+ve receiving hormone therapy, none (n=70) developed recurrence, compared to 10% (n=7) who did not.
Conclusions. Early findings suggest local recurrence rates are low at PHFT. All occurred early (at 2 years). Adjuvant radiotherapy and hormone therapy (if ER+ve) appeared to reduce risk. Further data collection and a subsequent audit is planned to determine the local recurrence rate and compare this to the BASO standard of <10% at 5 years.
Methods: A retrospective data analysis was undertaken of all women diagnosed with DCIS at Poole Hospital NHS Foundation Trust (PHFT) between January 2010 and December 2014, with median follow up of 48 months (range 24-72). Data was collected on demographics, treatment, histology, time to recurrence, and site/type of recurrence.
Results: 175 women were treated for DCIS from 2010-2014, mean age 62 years (range 36-91). The majority were detected via screening (67%) or surveillance (6%) mammography, however a quarter (26%) presented symptomatically. 66% (n=116) underwent wide local excision (WLE), 30% (n=53) mastectomy, 3% (n=5) primary hormone therapy, and 1% (n=2) no treatment. Of those undergoing WLE, 84% (n=97) received adjuvant radiotherapy, and 44% (n=54) with hormone receptor positive (ER+ve) disease received tamoxifen. After 48 months median follow up, following WLE 4.3% (n=5) developed local recurrence, 2.6% (n=3) ipsilateral recurrence, and 1.7% (3/175) in total contralateral disease. All local recurrences occurred at two years (3 invasive, 2 DCIS). Of those undergoing WLE who received radiotherapy, 3% (n=3/97) developed local/ipsilateral disease compared to 26% (n=5/19) who did not. Of those ER+ve receiving hormone therapy, none (n=70) developed recurrence, compared to 10% (n=7) who did not.
Conclusions. Early findings suggest local recurrence rates are low at PHFT. All occurred early (at 2 years). Adjuvant radiotherapy and hormone therapy (if ER+ve) appeared to reduce risk. Further data collection and a subsequent audit is planned to determine the local recurrence rate and compare this to the BASO standard of <10% at 5 years.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}